5273 completed, 189 terminated, 149 unknown, 92 recruiting. 5840 Phase 1, 108 Phase 2.
Follow Healthy: new trials by email Literature Review of Healthy trials Research Report on Healthy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of TBN Tetramethylpyrazine nitrone (TBN) tablet / Placebo - Healthy | Phase 1 | Not yet recruiting | Guangzhou Magpie Pharmaceuticals Co., Ltd. | 16 | 2028-09-01 | 2026-09-11 |
| A Clinical Trial of MK-7602 in Healthy Volunteers (MK-7602-006) MK-7602, Pyronaridine - Healthy | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 24 | 2027-01-04 | 2026-11-05 |
| A Phase 1, SAD and MAD to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral FB-101 in Healthy Adult Male Subjects FB-101, Placebo for FB-101 - Healthy | Phase 1 | Not yet recruiting | 1ST Biotherapeutics, Inc. | 72 | 2027-01-01 | 2026-09-02 |
| A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) MK-6916 - Healthy, Renal Impairment | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 32 | 2026-12-11 | 2026-11-06 |
| Study to Compare Blood Levels of Ceftriaxone Given by Suppository or Injection. A. Ceftriaxone (Roche ®) 500mg (slow intravenous injection), B. Ceftriaxone rectal dosage form test formulation 1 (1 x 500mg), C. Ceftriaxone rectal dosage form test formulation 2 (1 x 500mg) - Healthy | Phase 1 | Suspended | University of Oxford | 37 | 2026-12-01 | 2025-12-26 |
| Phase I Trial of RBD4059 in Chinese Healthy Participants RBD4059, Placebo - Healthy | Phase 1 | Not yet recruiting | Suzhou Ribo Life Science Co. Ltd. | 30 | 2026-12-01 | 2026-11-12 |
| A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012) Midazolam, Rosuvastatin, MK-6916 - Healthy | Phase 1 | Not yet recruiting | Merck Sharp & Dohme LLC | 18 | 2026-11-30 | 2026-10-07 |
| PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) 18F-PF974, 18F-florbetaben - Alzheimer s Disease, Mild Cognitive Impairment | Phase 1 | Recruiting | National Institute of Mental Health (NIMH) | 90 | 2026-11-18 | 2026-11-13 |
| First-in-Human Evaluation of [11C]JMJ-129-d2 for PDE4D Imaging in Healthy Volunteers [11C]JMJ-129-d2 - Healthy | Phase 1 | Recruiting | National Institute of Mental Health (NIMH) | 40 | 2026-11-18 | 2026-11-13 |
| A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy People BI 3821001, Placebo - Healthy | Phase 1 | Recruiting | Boehringer Ingelheim | 40 | 2026-11-03 | 2026-11-12 |
| A Study of Imlunestrant (LY3484356) in Healthy Female Participants Imlunestrant (Test), Imlunestrant (Reference), Omeprazole - Healthy | Phase 1 | Not yet recruiting | Eli Lilly and Company | 343 | 2026-11-01 | 2026-11-05 |
| A Study Assessing Eloralintide (LY3841136) in Healthy Participants Eloralintide - Healthy | Phase 1 | Not yet recruiting | Eli Lilly and Company | 90 | 2026-11-01 | 2026-11-13 |
| Psilocybin Efficacy With or Without Pimavanserin Pretreatment Psilocybin, Pimavanserin, Inactive Placebo - Mood (Psychological Function), Well Being | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | 20 | 2026-10-29 | 2026-11-02 |
| Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21) DZD8586, Rabeprazole - Healthy | Phase 1 | Recruiting | Dizal Pharmaceuticals | 26 | 2026-10-23 | 2026-11-06 |
| A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response ADX-001, Placebo - Healthy | Phase 1 | Recruiting | Adaxion Therapeutics | 88 | 2026-10-20 | 2026-11-05 |
| A Clinical Trial of MK-8644 in Healthy Participants and Participants With Psoriasis (MK-8644-001) MK-8644, Placebo for MK-8644 - Psoriasis, Healthy | Phase 1 | Recruiting | Merck Sharp & Dohme LLC | 132 | 2026-10-20 | 2026-10-27 |
| A Study in Healthy People to Compare How 2 Different Formulations of Vicadrostat / Empagliflozin Tablets Are Taken up in the Body Vicadrostat, Empagliflozin, Vicadrostat + empagliflozin - Healthy | Phase 1 | Recruiting | Boehringer Ingelheim | 36 | 2026-10-14 | 2026-10-29 |
| A Study to Test How Much BI 3034701 Gets Into the Blood in Healthy People When Given in Two Different Ways BI3034701 formulation II, BI3034701 formulation C1 - Healthy | Phase 1 | Recruiting | Boehringer Ingelheim | 30 | 2026-10-05 | 2026-10-19 |
| A Study of Single and Combination Lipase Dietary Supplements to Increase Fatty Acid Absorption in Generally Health Adults THRIVE4U™ TG Lipase, THRIVE4U™ Spectrum Lipases, Placebo - Digestive Symptoms, Gastrointestinal Symptoms | Phase 1 / Phase 2 | Not yet recruiting | Danisco | 50 | 2026-10-01 | 2026-10-23 |
| Study of CM583 in Healthy Participants CM583, Placebo - Healthy | Phase 1 | Not yet recruiting | Keymed Biosciences Co.Ltd | 40 | 2026-10-01 | 2026-09-16 |
Showing 20 of 5840. Sign in to see all of them.
Diabetes Mellitus (104) · Diabetes Mellitus, Type 2 (41) · Renal Insufficiency (36) · Obesity (34) · Alzheimer Disease (28) · Overweight (18) · Fasting (15) · Inflammation (15) · Influenza, Human (14) · COVID-19 (13) · Acquired Immunodeficiency Syndrome (12) · Arthritis, Rheumatoid (12) · Respiratory Aspiration (12) · Asthma (11) · Hepatic Insufficiency (11)
Nutritional and Metabolic Diseases (204) · Metabolic Diseases (166) · Pathological Conditions, Signs and Symptoms (153) · Endocrine System Diseases (132) · Glucose Metabolism Disorders (132) · Infections (98) · Nervous System Diseases (83) · Signs and Symptoms (81) · Mental Disorders (78) · Respiratory Tract Diseases (78) · Urogenital Diseases (74) · Virus Diseases (72) · Immune System Diseases (70) · Pathologic Processes (70) · RNA Virus Infections (67)
Metformin (117) · Midazolam (103) · Moxifloxacin (97) · Itraconazole (91) · Tablets (82) · Rosuvastatin Calcium (73) · Omeprazole (62) · Ritonavir (50) · Dabigatran (45) · Rifampin (44) · Digoxin (43) · Linagliptin (42) · empagliflozin (39) · Canagliflozin (36) · Sodium Chloride (36)
Boehringer Ingelheim (799) · Pfizer (361) · Eli Lilly and Company (288) · Janssen Research & Development, LLC (219) · Teva Pharmaceuticals USA (161) · Dr. Reddy's Laboratories Limited (156) · Mylan Pharmaceuticals Inc (147) · AstraZeneca (145) · Novo Nordisk A/S (125) · Merck Sharp & Dohme LLC (114) · Actavis Inc. (66) · Lakefront Biotherapeutics NV (63) · Wyeth is now a wholly owned subsidiary of Pfizer (56) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (55) · Daewoong Pharmaceutical Co. LTD. (53)
United States (2005) · Germany (473) · South Korea (388) · Belgium (348) · United Kingdom (333) · China (263) · Canada (220) · Japan (176) · Netherlands (146) · India (145) · Australia (108) · Singapore (87) · Switzerland (56) · France (50) · Sweden (45)
James D Carlson, Pharm. D. (50) · Dorian Williams, M.D. (42) · Ahmed Elshafeey, Ph.D. Pharma (34)
PMID 33128208, PMID 25078976, PMID 36451029, PMID 39175217, PMID 20844485, PMID 24868146, PMID 25078977, PMID 29856004, PMID 32348036, PMID 33969456, PMID 34473343, PMID 35061234, PMID 40455255, PMID 23497760, PMID 24408516, PMID 25345427, PMID 27140803, PMID 30908082, PMID 33654425, PMID 35344588, PMID 36919398, PMID 37917289, PMID 38054726, PMID 38267790, PMID 40117091, PMID 42563128, PMID 42684025, PMID 10454950, PMID 1490793, PMID 18832427, PMID 20126394, PMID 21480191, PMID 23811290, PMID 23926058, PMID 24491572, PMID 24669829, PMID 25350224, PMID 25659911, PMID 25681059, PMID 25697420, PMID 26381275, PMID 27136908, PMID 28230262, PMID 28349387, PMID 29363027, PMID 29500603, PMID 29749279, PMID 29912955, PMID 30098648, PMID 30412360
2014 (72), 2015 (71), 2018 (66), 2017 (61), 2019 (61), 2016 (49), 2023 (42), 2009 (32), 2025 (21), 2008 (14), 2005 (8), 2004 (3), R01DA003890 (2), R01GM036780 (2), R01MH123142 (2)